Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine whether the proposed first line treatment for falciparum malaria in this region (sulfadoxine-pyrimethamine + artesunate) would be no worse a treatment for vivax malaria that the standard vivax treatment of chloroquine. In areas where vivax and falciparum malaria co-exist misdiagnosis of vivax malaria as falciparum is not unlikely; it is important to know whether adequate treatment will be received in these cases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Treatments: Artemisinins; Artesunate; Chloroquine; Chloroquine diphosphate; Fanasil, pyrimethamine drug combination; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• microscopy confirmed P. vivax mono-infection

• age >2 years

• weight >5kg

• >1 asexual parasite per 10 fields

Exclusion Criteria:

• pregnant

• evidence of concomitant infection or serious disease

• recent use of antimalarial drugs

• severe malaria

• known allergy to study drugs